OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mato on the Efficacy of Fixed-Duration Venetoclax-Based Combo in CLL

April 8th 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Jain on High-Risk Mutations in Myelofibrosis

April 8th 2020

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

April 8th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Dr. Sapisochin on the Benefits of Living Donor Transplant in HCC

April 8th 2020

Gonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.

Dr. Mesa on Challenges in Myelofibrosis Treatment

April 8th 2020

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Dr. Boisen on Scoring System for Optimal Debulking in Ovarian Cancer

April 8th 2020

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Dr. Goy on the Progression of MCL Treatment

April 8th 2020

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast Cancer

April 8th 2020

Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast cancer.

Dr. Awan on Future of Combo Regimens in CLL Treatment Paradigm

April 8th 2020

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Dr. Cosgrove on the Utilization of PARP Inhibition in Ovarian Cancer

April 8th 2020

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Dr. Beltran on the Utility of Liquid Biopsies Versus Tissue Biopsies in CRPC-NE

April 8th 2020

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Marshall on the Push Toward Precision Medicine in CRC

April 8th 2020

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

Dr. Oh on the Role of Radiopharmaceuticals in mCRPC

April 8th 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Dr. O'Reilly on the Role of Germline Testing in Pancreatic Cancer

April 7th 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

April 7th 2020

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Dr. Otterson on When to Start Immunotherapy in NSCLC

April 7th 2020

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Dr. Danilov on Venetoclax Plus BTK Inhibitors in CLL

April 7th 2020

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC

April 7th 2020

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Dr. Cortes on the Safety Profile of Ruxolitinib in MPNs

April 7th 2020

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.